holger schünemann professor of clinical epidemiology , biostatistics and medicine
DESCRIPTION
Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine McMaster University, Hamilton, Canada Italian NCI „Regina Elena“, Rome , Italy. Principles guideline development and the GRADE system. Content. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/1.jpg)
Holger SchünemannProfessor of Clinical Epidemiology, Biostatistics and MedicineMcMaster University, Hamilton, CanadaItalian NCI „Regina Elena“, Rome, Italy
Principles guideline development and theGRADE system
![Page 2: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/2.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 3: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/3.jpg)
The GRADE approachClear separation of 2 issues:1) 4 categories of quality of evidence: very
low, low, moderate, or high quality? methodological considerations likelihood of systematic deviation from truth by outcome
2) Recommendation: 2 grades – weak/conditional or strong (for or against)? Quality of evidence only one factor Influenced by magnitude of effect(s) – balance
of benefits and harms, values and preferences, cost
*www.GradeWorkingGroup.org
![Page 4: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/4.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 5: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/5.jpg)
Implications of a strong recommendation Patients: Most people in this situation
would want the recommended course of action and only a small proportion would not
Clinicians: Most patients should receive the recommended course of action
Policy makers: The recommendation can be adapted as a policy in most situations
![Page 6: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/6.jpg)
Implications of a weak recommendation Patients: The majority of people in this
situation would want the recommended course of action, but many would not
Clinicians: Be prepared to help patients to make a decision that is consistent with their own values/decision aids and shared decision making
Policy makers: There is a need for substantial debate and involvement of stakeholders
![Page 7: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/7.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 8: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/8.jpg)
Answer
Same type of interpretation
![Page 9: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/9.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 10: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/10.jpg)
Determinants of quality - For body of evidence -
RCTs start high observational studies start low 5 factors that can lower quality
1. limitations of detailed design and execution2. inconsistency3. Indirectness/applicability4. publication bias5. Imprecision
3 factors can increase quality1. large magnitude of effect2. all plausible confounding may be working to reduce
the demonstrated effect or increase the effect if no effect was observed
3. dose-response gradient
![Page 11: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/11.jpg)
Assessing the quality of evidence
11
![Page 12: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/12.jpg)
1. Design and Execution
limitations lack of concealment intention to treat principle violated inadequate blinding loss to follow-up early stopping for benefit selective outcome reporting
Example: RCT suggests that danaparoid sodium is of benefit in treating HIT complicated by thrombosis Key outcome: clinicians’ assessment of when the
thromboembolism had resolved Not blinded – subjective judgement
![Page 13: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/13.jpg)
2. Inconsistency of results(Heterogeneity)
if inconsistency, look for explanation patients, intervention, outcome, methods
unexplained inconsistency downgrade quality
Bleeding in thrombosis-prophylaxed hospitalized patients seven RCTs 4 lower, 3 higher risk
![Page 14: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/14.jpg)
Example: Bleeding in the hospital
Dentali et al. Ann Int Med, 2007
![Page 15: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/15.jpg)
Judgment variation in size of effect overlap in confidence intervals statistical significance of heterogeneity I2
![Page 16: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/16.jpg)
Akl E, Barba M, Rohilla S, Terrenato I, Sperati F, Schünemann HJ. “Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer”. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006650.
Heparin or vitamin K antagonists for survival in patients with cancer
![Page 17: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/17.jpg)
Non-steroidal drug use and risk of pancreatic cancer
Capurso G, Schünemann HJ, Terrenato I, Moretti A, Koch M, Muti P, Capurso L, Delle Fave G. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories.
Aliment Pharmacol Ther. 2007 Oct 15;26(8):1089-99.
![Page 18: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/18.jpg)
3. Directness of Evidence
differences in populations/patients (mild versus severe COPD,
older, sicker or more co-morbidity) interventions (all inhaled steroids, new vs. old) outcomes (important vs. surrogate; long-term
health-related quality of life, short –term functional capacity, laboratory exercise, spirometry)
indirect comparisons interested in A versus B have A versus C and B versus C formoterol versus salmeterol versus tiotropium
![Page 19: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/19.jpg)
Alendronate
Risedronate
Placebo
Directness
interested in A versus B available data A vs C, B vs C
![Page 20: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/20.jpg)
4. Publication Bias & Imprecision Publication bias
number of small studies
![Page 21: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/21.jpg)
Egger M, Smith DS. BMJ 1995;310:752-54 21
I.V. Mg in acute myocardial infarctionPublication bias
Meta-analysisYusuf S.Circulation 1993
ISIS-4Lancet 1995
![Page 22: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/22.jpg)
Egger M, Cochrane Colloquium Lyon 2001 22
Funnel plotS
tand
ard
Err
or
Odds ratio0.1 0.3 1 3
3
2
1
0
100.6
Symmetrical:No publication bias
![Page 23: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/23.jpg)
Egger M, Cochrane Colloquium Lyon 2001 23
Funnel plotS
tand
ard
Err
or
Odds ratio0.1 0.3 1 3
3
2
1
0
100.6
Asymmetrical:Publication bias?
![Page 24: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/24.jpg)
Egger M, Smith DS. BMJ 1995;310:752-54 24
I.V. Mg in acute myocardial infarctionPublication bias
Meta-analysisYusuf S.Circulation 1993
ISIS-4Lancet 1995
![Page 25: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/25.jpg)
Egger M, Smith DS. BMJ 1995;310:752-54 25
Meta-analysis confirmed by mega-trials
![Page 26: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/26.jpg)
26
Publication bias (File Drawer Problem) Faster and multiple publication of
“positive” trials Fewer and slower publication of
“negative” trials
![Page 27: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/27.jpg)
5. Imprecision
small sample size small number of events
wide confidence intervals uncertainty about magnitude of effect
how to decide if CI too wide? grade down one level? grade down two levels?
extent to which confidence in estimate of effect adequate to support decision
![Page 28: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/28.jpg)
Example: Bleeding in the hospital
Dentali et al. Ann Int Med, 2007
![Page 29: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/29.jpg)
Offer all effective treatments? atrial fib at risk of stroke warfarin increases serious gi bleeding
3% per year
1,000 patients 1 less stroke 30 more bleeds for each stroke prevented
1,000 patients 100 less strokes 3 strokes prevented for each bleed
where is your threshold? how many strokes in 100 with 3% bleeding?
![Page 30: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/30.jpg)
01.0%
![Page 31: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/31.jpg)
01.0%
![Page 32: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/32.jpg)
01.0%
![Page 33: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/33.jpg)
01.0%
![Page 34: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/34.jpg)
What can raise quality?1. large magnitude can upgrade (RRR 50%)
very large two levels (RRR 80%) common criteria
everyone used to do badly almost everyone does well
oral anticoagulation for mechanical heart valves insulin for diabetic ketoacidosis
hip replacement for severe osteoarthritis2. dose response relation
(higher INR – increased bleeding)3. all plausible confounding may be working to reduce
the demonstrated effect or increase the effect if no effect was observed
![Page 35: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/35.jpg)
All plausible confounding
would result in an underestimate of the treatment effect Higher death rates in private for-
profit versus private not-for-profit hospitals patients in the not-for-profit hospitals
likely sicker than those in the for-profit hospitals
for-profit hospitals are likely to admit a larger proportion of well-insured patients than not-for-profit hospitals (and thus have more resources with a spill over effect)
![Page 36: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/36.jpg)
All plausible biases would result in an overestimate of effect Hypoglycaemic drug phenformin
causes lactic acidosis The related agent metformin is under
suspicion for the same toxicity. Large observational studies have
failed to demonstrate an association Clinicians would be more alert to lactic
acidosis in the presence of the agent
![Page 37: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/37.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 38: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/38.jpg)
Relevant clinical question?Example from a not so common disease
Clinical question:Population: Avian Flu/influenza A (H5N1) patientsIntervention: Oseltamivir (or Zanamivir) Comparison: No pharmacological interventionOutcomes: Mortality, hospitalizations,
resource use, adverse outcomes, antimicrobial resistanceSchunemann et al. The Lancet ID, 2007
![Page 39: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/39.jpg)
Methods – WHO Rapid Advice Guidelines for management of Avian Flu Applied findings of a recent systematic
evaluation of guideline development for WHO/ACHR
Group composition (including panel of 13 voting members):
clinicians who treated influenza A(H5N1) patients infectious disease experts basic scientists public health officers methodologists
Independent scientific reviewers: Identified systematic reviews, recent RCTs, case
series, animal studies related to H5N1 infection
![Page 40: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/40.jpg)
Evidence Profile
No of studies(Ref) Design Limitations Consistency Directness Other
considerations Oseltamivir Placebo Relative(95% CI )
Absolute(95% CI )
Mortality 0 - - - - - - - - - 9
5(TJ 06)
Randomised trial
No limitations One trial only Major uncertainty (-2)1
Imprecise or sparse data (-1)
- - OR 0.22(0.02 to 2.16)
- Very low
6
0 - - - - - - - - - - 7
5(TJ 06)
Randomised trial
No limitations One trial only Major uncertainty (-2)1
Imprecise or sparse data (-1)2
2/982(0.2%)
9/662(1.4%)
RR 0.149(0.03 to 0.69)
- Very low
8
53
(TJ 06)(DT 03)
Randomised trials
No limitations4 Important inconsistency(-1)5
Major uncertainty (-2)1
- - - HR 1.303
(1.13 to 1.50)-
Very low5
26
(TJ 06)Randomised trials
No limitations -7 Major uncertainty (-2)1
None - - - WMD -0.738
(-0.99 to -0.47)
Low4
0 - - - - - - - - - - 4
0 - - - - - - - - - - 7
09 - - - - - - - - - - 7
311
(TJ 06)Randomised trials
No limitations -12 Some uncertainty (-1)13
Imprecise or sparse data (-1)14
- - OR range15
(0.56 to 1.80)-
Low
0 - - - - - - - - - - 4
I mportance
Summary of findings
Cost of drugs
Outbreak control
Resistance
Serious adverse effects (Mention of significant or serious adverse effects)
Minor adverse effects 10 (number and seriousness of adverse effects)
Viral shedding (Mean nasal titre of excreted virus at 24h)
Duration of disease (Time to alleviation of symptoms/median time to resolution of symptoms – influenza cases only)
Duration of hospitalization
LRTI (Pneumonia - influenza cases only)
Healthy adults:
Hospitalisation (Hospitalisations from influenza – influenza cases only)
Quality assessmentNo of patients Effect
Quality
Oseltamivir for treatment of H5N1 infection:
-
-
![Page 41: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/41.jpg)
Oseltamivir for Avian FluSummary of findings: No clinical trial of oseltamivir for treatment
of H5N1 patients. 4 systematic reviews and health technology
assessments (HTA) reporting on 5 studies of oseltamivir in seasonal influenza. Hospitalization: OR 0.22 (0.02 – 2.16) Pneumonia: OR 0.15 (0.03 - 0.69)
3 published case series. Many in vitro and animal studies. No alternative that is more promising at
present. Cost: ~ 40$ per treatment course
Schunemann et al. Lancet ID, 2007
& PLOS Medicine 2007
![Page 42: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/42.jpg)
Determinants of the strength of recommendation
Factors that can strengthen a recommendation
Comment
Quality of the evidence The higher the quality of evidence, the more likely is a strong recommendation.
Balance between desirable and undesirable effects
The larger the difference between the desirable and undesirable consequences, the more likely a strong recommendation warranted. The smaller the net benefit and the lower certainty for that benefit, the more likely weak recommendation warranted.
Values and preferences The greater the variability in values and preferences, or uncertainty in values and preferences, the more likely weak recommendation warranted.
Costs (resource allocation) The higher the costs of an intervention – that is, the more resources consumed – the less likely is a strong recommendation warranted
![Page 43: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/43.jpg)
Example: Oseltamivir for Avian Flu
Recommendation: In patients with confirmed or strongly suspected infection with avian influenza A (H5N1) virus, clinicians should administer oseltamivir treatment as soon as possible (????? recommendation, very low quality evidence).
Schunemann et al. The Lancet ID, 2007
![Page 44: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/44.jpg)
Example: Oseltamivir for Avian Flu
Recommendation: In patients with confirmed or strongly suspected infection with avian influenza A (H5N1) virus, clinicians should administer oseltamivir treatment as soon as possible (strong recommendation, very low quality evidence). Values and PreferencesRemarks: This recommendation places a high value on the prevention of death in an illness with a high case fatality. It places relatively low values on adverse reactions, the development of resistance and costs of treatment.
Schunemann et al. The Lancet ID, 2007
![Page 45: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/45.jpg)
Other explanations
Remarks: Despite the lack of controlled treatment data for H5N1, this is a strong recommendation, in part, because there is a lack of known effective alternative pharmacological interventions at this time.
The panel voted on whether this recommendation should be strong or weak and there was one abstention and one dissenting vote.
![Page 46: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/46.jpg)
Strength of recommendation
“The strength of a recommendation reflects the extent to which we can, across the range of patients for whom the recommendations are intended, be confident that desirable effects of a management strategy outweigh undesirable effects.”
Strong or weak/conditional
![Page 47: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/47.jpg)
Quality of evidence & strength of recommendation Linked but no automatism Other factors beyond the quality of
evidence influence our confidence that adherence to a recommendation causes more benefit than harm
Systems/approaches failed to make this explicit
GRADE separates quality of evidence from strength of recommendation
![Page 48: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/48.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 49: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/49.jpg)
Creating a new GRADEpro file
![Page 50: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/50.jpg)
![Page 51: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/51.jpg)
![Page 52: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/52.jpg)
Profile groups
Profiles
![Page 53: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/53.jpg)
Profiles: Questions
![Page 54: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/54.jpg)
![Page 55: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/55.jpg)
![Page 56: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/56.jpg)
![Page 57: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/57.jpg)
![Page 58: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/58.jpg)
![Page 59: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/59.jpg)
Importing a RevMan 5 file of a systematic review
Imported data from RevMan 5 file: • outcomes• meta-analyses results• bibliographic information
![Page 60: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/60.jpg)
![Page 61: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/61.jpg)
Managing outcomes to include a maximum of 7
![Page 62: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/62.jpg)
Entering/editing information for dichotomous outcomes
![Page 63: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/63.jpg)
Entering/editing information to grade the quality of the evidence
![Page 64: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/64.jpg)
![Page 65: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/65.jpg)
![Page 66: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/66.jpg)
![Page 67: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/67.jpg)
![Page 68: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/68.jpg)
![Page 69: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/69.jpg)
![Page 70: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/70.jpg)
![Page 71: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/71.jpg)
![Page 72: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/72.jpg)
![Page 73: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/73.jpg)
Content Describe the grade of recommendation
and what each category means: strong/weak and optional language
How the quality of evidence can be upgraded/down-graded
What happens when you’re recommending something not be done?
Maybe provide some ID-type examples if possible - I’m attaching our clinical questions that may be used as examples?
Provide a quick tutorial of GRADEPro Questions
![Page 74: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/74.jpg)
![Page 75: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/75.jpg)
Example: Oseltamivir for Avian Flu
Recommendation: In patients with confirmed or strongly suspected infection with avian influenza A (H5N1) virus, clinicians should administer oseltamivir treatment as soon as possible (strong recommendation, very low quality evidence). Values and PreferencesThis recommendation places a high value on the prevention of death in an illness with a high case fatality. It places relatively low values on adverse reactions, the development of resistance and costs of treatment. RemarksDespite the lack of controlled treatment data for H5N1, this is a strong recommendation, in part, because there is a lack of known effective alternative pharmacological interventions at this time.
Schunemann et al. The Lancet ID, 2007
![Page 76: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/76.jpg)
Confidence in evidence
There always is evidence “When there is a question there is
evidence” Research evidence alone is never
sufficient to make a clinical decision Better research greater confidence
in the evidence and decisions
![Page 77: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/77.jpg)
77
Sequence gen.
Allocation concealment
Blinding/Masking
Intention-to-treat analysis
Blinding/Masking
Baseline
Allocation
A B
Intervention No interv.
Follow up Follow up
Outcome Outcome
Method
Random?
Selectionbias?
Performance bias?
Attritionbias?
Detectionbias?
Question
Factors leading to bias?Can you explain them?
P-values and confidence intervals important?
CONSENSUS ALWAYS REQUIRED
![Page 78: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/78.jpg)
Limitations of existing systems
confuse quality of evidence with strength of recommendations
lack well-articulated conceptual framework
criteria not comprehensive or transparent GRADE unique
breadth, intensity of development process wide endorsement and use conceptual framework comprehensive, transparent criteria
![Page 79: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/79.jpg)
GRADE WORKING GROUP
Grades of Recommendation Assessment,
Development and Evaluation
*Grade Working Group. CMAJ 2003, BMJ 2004, BMC 2004, BMC 2005, AJRCCM 2006, BMJ 2008
![Page 80: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/80.jpg)
GRADE Working GroupDavid Atkins, chief medical officera Dana Best, assistant professorb Martin Eccles, professord Francoise Cluzeau, lecturerx
Yngve Falck-Ytter, associate directore Signe Flottorp, researcherf Gordon H Guyatt, professorg Robin T Harbour, quality and information director h Margaret C Haugh, methodologisti David Henry, professorj Suzanne Hill, senior lecturerj Roman Jaeschke, clinical professork Regina Kunx, Associate ProfessorGillian Leng, guidelines programme directorl Alessandro Liberati, professorm Nicola Magrini, directorn
James Mason, professord Philippa Middleton, honorary research fellowo Jacek Mrukowicz, executive directorp Dianne O’Connell, senior epidemiologistq Andrew D Oxman, directorf Bob Phillips, associate fellowr Holger J Schünemann, professorg,s Tessa Tan-Torres Edejer, medical officert David Tovey, Editory
Jane Thomas, Lecturer, UKHelena Varonen, associate editoru Gunn E Vist, researcherf John W Williams Jr, professorv Stephanie Zaza, project directorw
a) Agency for Healthcare Research and Quality, USA b) Children's National Medical Center, USAc) Centers for Disease Control and Prevention, USAd) University of Newcastle upon Tyne, UKe) German Cochrane Centre, Germanyf) Norwegian Centre for Health Services, Norwayg) McMaster University, Canadah) Scottish Intercollegiate Guidelines Network, UKi) Fédération Nationale des Centres de Lutte Contre le Cancer, Francej) University of Newcastle, Australiak) McMaster University, Canadal) National Institute for Clinical Excellence, UKm) Università di Modena e Reggio Emilia, Italyn) Centro per la Valutazione della Efficacia della Assistenza Sanitaria, Italyo) Australasian Cochrane Centre, Australia p) Polish Institute for Evidence Based Medicine, Polandq) The Cancer Council, Australiar) Centre for Evidence-based Medicine, UKs) National Cancer Institute, Italyt) World Health Organisation, Switzerland u) Finnish Medical Society Duodecim, Finland v) Duke University Medical Center, USA w) Centers for Disease Control and Prevention, USAx) University of London, UKY) BMJ Clinical Evidence, UK
![Page 81: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/81.jpg)
GRADE Uptake World Health Organization National Institute Clinical Excellence (NICE) Allergic Rhinitis in Asthma Guidelines (ARIA) American Thoracic Society British Medical Journal Infectious Disease Society of America American College of Chest Physicians UpToDate American College of Physicians Cochrane Collaboration Infectious Disease Society of America European Society of Thoracic Surgeons Clinical Evidence Agency for Health Care Research and Quality (AHRQ) Over 20 major organizations
![Page 82: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/82.jpg)
The GRADE approachClear separation of 2 issues:1) 4 categories of quality of evidence: very
low, low, moderate, or high quality? methodological quality of evidence likelihood of systematic deviation from truth by outcome
2) Recommendation: 2 grades – weak/conditional or strong (for or against)? Quality of evidence only one factor Influenced by magnitude of effect(s) – balance
of benefits and harms, values and preferences, cost
*www.GradeWorkingGroup.org
![Page 83: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/83.jpg)
GRADE Quality of Evidence
“Extend of confidence on how adequate the estimate of effect is to support decision”
high: considerable confidence in estimate of effect.
moderate: further research likely to have impact on confidence in estimate, may change estimate.
low: further research is very likely to impact on confidence, likely to change the estimate.
very low: any estimate of effect is very uncertain
![Page 84: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/84.jpg)
Developing recommendations
![Page 85: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/85.jpg)
Conclusion
clinicians, policy makers need summaries that separate: quality of evidence strength of recommendations
explicit rules transparent, informative
GRADE four categories of quality of evidence two grades for strength of recommendations transparent, systematic by and across outcomes applicable to diagnosis wide adoption
![Page 86: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/86.jpg)
![Page 87: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/87.jpg)
Consistency of results
consistency of results if inconsistency, look for explanation
patients, intervention, outcome, methods unexplained inconsistency downgrade
quality oxygen for day-to-day dyspnea in COPD with
exercise hypoxemia five cross-over RCTs oxygen versus placebo 4 no benefit, 1 substantial benefit
![Page 88: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/88.jpg)
Evidence profiles
![Page 89: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/89.jpg)
Directness of Evidence
indirect comparisons interested in A versus B have A versus C and B versus C formoterol versus salmeterol versus tiotropium Acetylcysteine alone for Pulmonary Fibrosis
(all that is available is Acetylcysteine + Prednisone + Azathioprine vs. Prednisone + Azathioprine)
![Page 90: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/90.jpg)
Directness of Evidence
differences in patients (inhalers for mild versus moderate to
severe COPD) interventions (all inhaled steroids versus those
used in clinical trials – drug class effect) outcomes (long-term health-related quality of
life, short –term functional capacity, laboratory exercise, spirometry)
![Page 91: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/91.jpg)
Reporting Bias & Imprecision reporting bias
reporting of studies publication bias
number of small studies reporting of outcomes
small sample size small number of events wide confidence intervals uncertainty about magnitude of effect
![Page 92: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/92.jpg)
Differences in exercise capacity in short-term randomized trials of oxygen in COPD patients.
![Page 93: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/93.jpg)
What can raise quality?
large magnitude can upgrade (RRR 50%) very large two levels (RRR 80%) common criteria
everyone used to do badly almost everyone does well
Insulin in diabetic ketoacidosis dose response relation
(smoking - cancer)
![Page 94: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/94.jpg)
The clinical scenario
A 68 year old male long-term patient of yours. He suffers from COPD but is unable to stop smoking after over 30 years of tobacco use. He has been taking beta-carotene supplements for several months because someone in the “healthy food” store recommended it to prevent cancer. He wants to know whether this will prevent him from getting cancer and whether he should use beta-carotene.
![Page 95: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/95.jpg)
The clinical question
Population: In patients with COPDIntervention: does beta-carotene supplComparison: compared to no suppl.Outcomes: reduce the risk of lung
cancer?
![Page 96: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/96.jpg)
Where do you look for an answer?
![Page 97: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/97.jpg)
Clinical Practice Guidelines
Systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances
Institute of Medicine, 1992
![Page 98: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/98.jpg)
![Page 99: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/99.jpg)
Determinants of quality RCTs start high observational studies start low 5 Factors that lower quality (bias) 3 Factors that increase quality (bias
is unlikely to explain observed effect) Final quality by outcome:
High Moderate Low Very low
![Page 100: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/100.jpg)
Design and Execution
limitations lack of concealment intention to treat principle violated inadequate blinding loss to follow-up early stopping for benefit
13 RCTs bacterial extract (immunomodulation) for preventing exacerbation unclear concealment of randomization questionable intention to treat inadequate attention to loss to follow-up
![Page 101: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/101.jpg)
Consistency of results
consistency of results if inconsistency, look for explanation
patients, intervention, outcome, methods unexplained inconsistency downgrade
quality oxygen for day-to-day dyspnea in COPD with
exercise hypoxemia five cross-over RCTs oxygen versus placebo 4 no benefit, 1 substantial benefit
![Page 102: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/102.jpg)
Directness of Evidence
indirect comparisons interested in A versus B have A versus C and B versus C formoterol versus salmeterol versus tiotropium
differences in patients (mild versus severe COPD) interventions (all inhaled steroids) outcomes (long-term health-related quality of
life, short –term functional capacity, laboratory exercise, spirometry)
![Page 103: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/103.jpg)
How should recommendations be formulated and presented? Few written standards exist For strong recommendations, the GRADE
working group has suggested adopting terminology such as, “We recommend…” or “Clinicians should…”.
For weak recommendation, they should use less definitive wording, “We suggest…” or “Clinicians might…”.
![Page 104: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/104.jpg)
Clinicians and patients want to know!
1) UpToDate® Users 2) Mini Medical School attendees*:
• Participants preferred to know about the uncertainty relating to outcomes of a treatment or a test
• more interested in knowing about uncertainty relating to benefits than harms (96% vs. 90%; P<0.001).
• strong preference to be informed about the quality of evidence that supports a recommendation.
*Akl et al. J Clin Epi, 2007, in press
![Page 105: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/105.jpg)
GRADE Quality of Evidence
Extent to which confidence in estimate of effect adequate to support decision
high: considerable confidence in estimate of effect.
moderate: further research likely to have impact on confidence in estimate, may change estimate.
low: further research is very likely to impact on confidence, likely to change the estimate.
very low: any estimate of effect is very uncertain
![Page 106: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/106.jpg)
There always is evidence
The better the research and the evidence, the more confident the decision
Evidence alone is never sufficient to make a clinical decision
![Page 107: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/107.jpg)
Do evidence based guidelines make a difference?Non-rigorous guidelines:• Create noise & bias• Make more aggressive recommendations• Can harm patients and impair research efforts• Can reduce credibility of professional societiesEvidence-based clinical practice guidelines can:• reduce delivery of inappropriate care• support introduction of new knowledge into clinical
practice
Grimshaw et al (1992); Woolf et al (1999);
Fretheim et al (2002)
![Page 108: Holger Schünemann Professor of Clinical Epidemiology , Biostatistics and Medicine](https://reader035.vdocument.in/reader035/viewer/2022062501/56816474550346895dd6599b/html5/thumbnails/108.jpg)